Treatment with Remicade (infliximab) in neurosarcoidosis patients is associated with favorable imaging and clinical treatment responses, new research shows. The study, “Infliximab for the treatment of CNS sarcoidosis,” was published in the journal Neurology. Neurosarcoidosis occurs in about 5% to 15% of patients with sarcoidosis…

The Lung Allocation Score (LAS) system, which is used to prioritize patients awaiting lung transplant, may not accurately reflect disease severity risks for people with pulmonary sarcoidosis, a new study reports. Results showed that several factors accounted for in the LAS remain significant predictors of mortality for patients on…

People with autoimmune diseases such as sarcoidosis are not at higher risk of worse outcomes following lung or heart-lung transplants compared with people without such diseases, a new single-center study shows. The findings that autoimmune patients fare as well as others following such transplants refute the long standard approach…

Treatment with repository corticotropin (RCI), such as Acthar Gel, may protect the lungs from prednisone-induced damage and improve the outcome in patients with symptomatic pulmonary sarcoidosis, according to results of a clinical trial (NCT02188017). The findings, “Repository Corticotropin For Chronic Pulmonary Sarcoidosis.” were published in the journal Lung.

I felt vindicated last year when researchers reported Lyme disease could potentially trigger sarcoidosis. I’ve been trying to get physicians to see a link between the two for years. I used to expect some dramatic “aha” moment when I reported that my sarcoidosis arrived a year after my Lyme…

Since I received a diagnosis of sarcoidosis in my lungs, I have made frequent visits to my pulmonologist to monitor my condition to see if it is progressing and to assess my overall health. On…

A new grant program worth up to $3.5 million, from the Ann Theodore Foundation, is seeking researchers in the U.S. who are working to advance knowledge and understanding of sarcoidosis. The Milken Institute, a nonprofit think tank, is accepting applications from American research institutions for the Ann Theodore…

Cells of the innate immune system called monocytes can be useful biomarkers to predict the outcomes of people with sarcoidosis, a recent study has found. The findings showed that patients with low levels of blood monocytes at diagnosis were more likely to achieve remission after two years and had…

ATYR1923, a candidate therapy for pulmonary sarcoidosis, binds specifically to the neuropilin-2 (NRP2) receptor protein, which is located at the surface of immune cells responsible for inflammation and granuloma formation in lung sarcoidosis, the treatment’s developer, aTyr Pharma, has announced. These findings are described in two posters,…